3 January 2018
Join Dr. Kiri Granger, Director of Neuroscience, Cambridge Cognition and Dr. Steve Brannan, Chief Medical Officer, Karuna Pharmaceuticals Inc. for a live discussion on improving clinical trial success in schizophrenia.
The webinar takes place on Tuesday, January 30, 2018 at 11am EST (4pm GMT).
30 November 2017
We’re delighted to announce that both CANTAB Mobile and CANTAB Insight medical devices, designed for the assessment of cognitive health in clinical practice, have been approved for marketing in Australia by the Therapeutic Goods Administration (TGA) (ARTG No. 294119).
28 November 2017
Cognition Kit wearable technology demonstrates high compliance among patients with major depressive disorder (MDD)
At the 2017 International CNS Summit in Boca Raton, Florida, we were pleased to release the positive results from a pilot study into the evaluation of cognition and mood using wearable technology in patients with MDD.
13 November 2017
Cambridge Cognition are attending the Collaborating for Novel Solutions (CNS) Summit: 16th-19th November 2017.
8 November 2017
We’re pleased to announce that Hogrefe Psykologien Kustannus Oy is now an exclusive distributor of CANTAB software products for use in Finland by academic researchers and healthcare professionals.
6 November 2017
New data demonstrates possibility for speech recognition and online assessments to enhance clinical trials in Alzheimer’s disease.
12 September 2017
A new system being developed by Cambridge Cognition with Innovate UK funding will provide a non-invasive, inexpensive means of accurately monitoring levels of pain by combining artificial intelligence technology and cognitive neuroscience.